Table 1 Incidence of thrombotic events... | American Society of Hematology

Table 1

Incidence of thrombotic events and bleedings in patients with polycythemia vera or essential thrombocythemia

Reference	MPN	Design	Patients (n)	Total patient years	Cyto-reduction (%)	Anti-platelet agents (%)	Thrombosis % per year						Bleeding % per year
Reference	MPN	Design	Patients (n)	Total patient years	Cyto-reduction (%)	Anti-platelet agents (%)	All	Arterial	MI	Ischemic stroke	Venous	DVT and/or PE	Overall	Intra-cranial	Gastro-intestinal	Other
GISP²	PV	Retrospective	1213	7400	69	NA	3.2	2.0	0.7	0.5	1.2	0.6	NA	NA	NA	NA
Passamonti et al³	PV	Retrospective	396	4184	86	57	1.1	0.7	0.2	0.2	0.4	0.3	NA	NA	NA	NA
Landolfi et al⁴³	PV	Prospective randomized	518	∼739 per arm	57	49	4.9*1.7†	2.6*0.9†	0.2*0.1†	1.1*0.2†	2.3*0.8†	1.5*0.5†	1.9*3.1†	0.2*0.1†	0*0.2†	1.6*2.7†
Marchioli et al⁴	PV	Prospective observational	1638	4390	62	58	4.9	2.6	0.9	0.8	2.3	1.3	2.9	0.8		2.1
De Stefano et al²⁹	PV	Retrospective‡	235	1419	66	71	6.0	3.5§	0.3	1.0	2.5§	2.1	0.9	0.1	0.6	0.2
Cortelazzo et al³⁰	ET	Retrospective	100	303	74	1	6.6	4.6	1.0	NA	2.0	1.0	0.3	0	0.3	0
Colombi et al³¹	ET	Retrospective	103	489	65	72	2.2	2.0	0.4	0.6	0.2	0.2	1.8	0	1.2	0.6
Harrison et al³²	ET	Prospective randomized	809	2653	72\|\|	100	2.6	2.0	0.7	0.6	0.6	0.6	1.1	0.2	0.6	0.3
Passamonti et al³³	ET	Retrospective	605	4596	67	33¶	1.3	1.1	0.3	0.4	0.2	0.3	NA	NA	NA	NA
Carobbio et al³⁴	ET	Retrospective	1063	5130	51	66	2.3	1.6	0.5	NA	0.7	NA	0.8	NA	0.6	NA
De Stefano et al²⁹	ET	Retrospective	259‡	1533	75	75	5.2	3.3§	0.4	0.4	1.9§	1.5	0.9	0.3	0.5	0.1
Carobbio et al³⁵; Finazzi et al^36,#	ET	Retrospective	891	NA	57	68	1.8	1.2	0.3	NA	0.6	NA	0.8	0.03	0.4	0.4
Palandri et al³⁷	ET	Retrospective	565	4433	86	95	NA	NA	NA	NA	NA	NA	1.4	0.06	0.3	1.0

Reference	MPN	Design	Patients (n)	Total patient years	Cyto-reduction (%)	Anti-platelet agents (%)	Thrombosis % per year						Bleeding % per year
Reference	MPN	Design	Patients (n)	Total patient years	Cyto-reduction (%)	Anti-platelet agents (%)	All	Arterial	MI	Ischemic stroke	Venous	DVT and/or PE	Overall	Intra-cranial	Gastro-intestinal	Other
GISP²	PV	Retrospective	1213	7400	69	NA	3.2	2.0	0.7	0.5	1.2	0.6	NA	NA	NA	NA
Passamonti et al³	PV	Retrospective	396	4184	86	57	1.1	0.7	0.2	0.2	0.4	0.3	NA	NA	NA	NA
Landolfi et al⁴³	PV	Prospective randomized	518	∼739 per arm	57	49	4.9*1.7†	2.6*0.9†	0.2*0.1†	1.1*0.2†	2.3*0.8†	1.5*0.5†	1.9*3.1†	0.2*0.1†	0*0.2†	1.6*2.7†
Marchioli et al⁴	PV	Prospective observational	1638	4390	62	58	4.9	2.6	0.9	0.8	2.3	1.3	2.9	0.8		2.1
De Stefano et al²⁹	PV	Retrospective‡	235	1419	66	71	6.0	3.5§	0.3	1.0	2.5§	2.1	0.9	0.1	0.6	0.2
Cortelazzo et al³⁰	ET	Retrospective	100	303	74	1	6.6	4.6	1.0	NA	2.0	1.0	0.3	0	0.3	0
Colombi et al³¹	ET	Retrospective	103	489	65	72	2.2	2.0	0.4	0.6	0.2	0.2	1.8	0	1.2	0.6
Harrison et al³²	ET	Prospective randomized	809	2653	72\|\|	100	2.6	2.0	0.7	0.6	0.6	0.6	1.1	0.2	0.6	0.3
Passamonti et al³³	ET	Retrospective	605	4596	67	33¶	1.3	1.1	0.3	0.4	0.2	0.3	NA	NA	NA	NA
Carobbio et al³⁴	ET	Retrospective	1063	5130	51	66	2.3	1.6	0.5	NA	0.7	NA	0.8	NA	0.6	NA
De Stefano et al²⁹	ET	Retrospective	259‡	1533	75	75	5.2	3.3§	0.4	0.4	1.9§	1.5	0.9	0.3	0.5	0.1
Carobbio et al³⁵; Finazzi et al^36,#	ET	Retrospective	891	NA	57	68	1.8	1.2	0.3	NA	0.6	NA	0.8	0.03	0.4	0.4
Palandri et al³⁷	ET	Retrospective	565	4433	86	95	NA	NA	NA	NA	NA	NA	1.4	0.06	0.3	1.0

Arterial thrombosis included fatal and nonfatal acute coronary syndromes (ie, MI, and unstable angina); cerebrovascular disease (ischemic stroke and transient ischemic attack); and occlusion of retinal, abdominal, or peripheral arteries. Venous thrombosis included fatal and nonfatal DVT; PE; superficial vein thrombosis; and occlusion of retinal, splanchnic, or cerebral veins.

NA, not available.

Without aspirin.

†

With aspirin.

‡

Cohort with previous thrombosis, studied from first thrombosis.

Incidence of first thrombotic recurrences.

Percent of patients on cytoreduction at trial closure.

Antiplatelet agents only.

Both studies refer to the same patient cohort.

View Large

This Feature Is Available To Subscribers Only